ASSESSMENT OF DIASTOLIC FUNCTION AND SERUM NGAL AND CYSTATIN C CONTENT IN ARTERIAL HYPERTENSION IN PATIENTS WITH STAGE 1 OBESITY

Authors:

Abstract:

The purpose of the study was to investigate changes in central hemodynamic parameters, left ventricular diastolic function, and markers of renal dysfunction in patients with arterial hypertension associated with obesity. A total of 53 patients (mean age 52.6±2.5 years) with stage II, grade 2 arterial hypertension were examined and, according to their body mass index, were divided into two groups: group 1 – 25 patients with normal body weight, and group 2 – 28 patients with grade I obesity. The control group included 20 persons (mean age 52.1±2.3 years) with cardiovascular risk factors and normal blood pressure. All participants underwent clinical and laboratory examinations, including 24-hour blood pressure monitoring, echocardiography with assessment of transmitral Doppler blood flow, and enzyme-linked immunoassay was used to determine serum cystatin C and neutrophil gelatinase-associated lipocalin levels. Statistical analysis of the results was performed using the Statistica 10.0 software. It has been established that in patients with arterial hypertension combined with obesity, there is an increased incidence of concentric and eccentric left ventricular hypertrophy and impaired left ventricular diastolic function. It has been determined that in patients with arterial hypertension associated with obesity, morphofunctional changes in the heart and kidneys occurring in parallel, including the progression of diastolic dysfunction, increasing left ventricular myocardial mass index and serum levels of cystatin C and neutrophil gelatinase-associated lipocalin, and reducing the estimated glomerular filtration rate.

Keywords:

arterial hypertension obesity left ventricular remodeling diastolic function neutrophil gelatinase-associated lipocalin cystatin C

References:

1. Budnik TV, Khaitovych MV, Balatska NI. ANCA-asotsiyovani nefryty u ditey: suchasni pohlyady na diahnostyku ta likuvalnu taktyku (ohlyad literatury). Child’s Health. 2026;21(2):111–124. DOI: 10.22141/2224-0551.21.2.2026.1949 [in Ukrainian].
2. Korost YaV, Lavryshyn YuM, Lapshyna RO, Lapshyn OV. Vplyv zabrudnennya povitrya na perebih arterialnoyi hipertenziyi u meshkantsiv mista Kyyeva. Health of the Nation. 2026; N2:66-70 DOI: https://doi.org/10.32782/2077-6594/2026.2/08 [in Ukrainian].
3. Grassi G, Hering D, Ram CVS, Mancia G. Obesity-Related Hypertension: An Emerging Clinical Phenotype. Am J Cardiol. 2026;272:12-19. doi: 10.1016/j.amjcard.2026.05.002
4. Ismail M, Abdelhamid N, Hasanin HM, Hamed HM, Motawie AA, Kamel S, et al. Early Diagnostic and Prognostic Value of the Urinary TIMP-2 and IGFBP-7 in Acute Kidney Injury in Critically Ill Children. Indian J Crit Care Med. 2024 Oct;28(10):970-976. doi: 10.5005/jp-journals-10071-24815.
5. Kruszewska J, Cudnoch-Jedrzejewska A, Czarzasta K. Remodeling and Fibrosis of the Cardiac Muscle in the Course of Obesity-Pathogenesis and Involvement of the Extracellular Matrix. Int J Mol Sci. 2022 Apr 11;23(8):4195. doi: 10.3390/ijms23084195.
6. Mandry D, Girerd N, Lamiral Z, Huttin O, Filippetti L, Micard E, et al. Arterial and Cardiac Remodeling Associated With Extra Weight Gain in an Isolated Abdominal Obesity Cohort. Front Cardiovasc Med. 2021;8:771022. doi: 10.3389/fcvm.2021.771022.
7. Matsushita K, Ballew SH, Wang AY, Kalyesubula R, Schaeffner E, Agarwal R. Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease. Nat Rev Nephrol. 2022;18(11):696-707. doi: 10.1038/s41581-022-00616-6.
8. Ottosen CI, Nadruz W, Inciardi RM, Johansen ND, Fudim M, Biering-Sørensen T. Diastolic dysfunction in hypertension: a comprehensive review of pathophysiology, diagnosis, and treatment. Eur Heart J Cardiovasc Imaging. 2024;25(11):1525-1536. doi: 10.1093/ehjci/jeae178.
9. Parisien-La Salle S, Tsai CH, Newman AJ, Chan JM, Milks J, Adler G et al. Unmasking Hormonal Mechanisms of Hypertension in Obesity. medRxiv [Preprint]. 2025:2025.11.18.25340514. doi: 10.1101/2025.11.18.25340514. Update in: JACC Basic Transl Sci. 2026;11(4):101526. doi: 10.1016/j.jacbts.2026.101526.
10. Ringwald-de Meyer S, de La Harpe R, Vollenweider P, Marques-Vidal P, Vaucher J. Factor associated with and risk of cardiovascular disease in people with uncontrolled hypertension. Sci Rep. 2025;15(1):375. doi: 10.1038/s41598-024-84824-z.
11. Singh A, Ahmed F, Paul S, Sethi P, Pandey S, Priyatma, et al. Obesity and subclinical kidney injury: a biomarker based assessment in Asian Indian adults. BMC Nutr. 2026 Jan 24;12(1):39. doi: 10.1186/s40795-026-01250-2.
12. Swift DL, Ross LM, Laddu DR, Conroy MB, German CA, Evangelista LS; on behalf the American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Hypertension; Stroke Council. Role of Physical Activity in Obesity Treatment and Cardiometabolic Health: A Scientific Statement From the American Heart Association. Circulation. 2026 Jul 7;154(1):e1-e16. doi: 10.1161/CIR.0000000000001441.
13. Wadhera RK, Dhruva SS, Bikdeli B, Bonaca MP, Kittleson MM, Ko DT, et al. Cardiovascular Statistics in the United States, 2026: JACC Stats. J Am Coll Cardiol. 2026 Mar 10;87(9):1094-1134. doi: 10.1016/j.jacc.2025.12.027.
14. Wagner KD, Wagner N. The senescence markers p16INK4A, p14ARF/p19ARF, and p21 in organ development and homeostasis. Cells. 2022;11(12):1966. doi: 10.3390/cells11121966.
15. Zhang L, Al-Saeedi M, Denic A, Jordan KL, Yang N, Yuan F, et al. Renal podocyte senescence in human obesity detected by urinary extracellular vesicles. EBioMedicine. 2026 Feb;124:106116. doi: 10.1016/j.ebiom.2025.106116.

Publication:

«World of Medicine and Biology» Vol. 22 No. 97 (2026), pp. 13-18
UDC 616.12-008.331.1-056.257-078(045)

DOI:

https://doi.org/10.26724/2079-8334-2026-3-97-13-18